(UroToday.com) The 2025 AUA annual meeting featured an upper tract urothelial carcinoma session and a presentation by Dr. Jiwei Huang discussing results of a phase II study of tislelizumab as ...

Oncologists at AUA 2025 share promising data, including sasanlimab, cretostimogene grenadenorepvec, and TAR-200 in NMIBC.

Long-term data from QUILT-3.032 showed that NAI plus BCG shows sustained responses in BCG-unresponsive bladder cancer with 84 ...

Paul Cauthen is making it clear that he is determined not to slow down or back down as he battles cancer. The country music singer shared a handful of Instagram stories across the past week that ...

People with the hereditary disease familial adenomatous polyposis (FAP) have a greatly increased risk of developing a malignant tumor of the duodenum. Researchers have now discovered a mechanism in ...

Researchers with City of Hope ®, one of the largest and most advanced cancer research and treatment organizations in the U.S. with its National Medical Center named top 5 in the nation for cancer by U ...

Summit Therapeutics stock tumbled 37% on Friday afternoon after the U.S. Food and Drug Administration (FDA) approved its ...

Penpulimab is approved for multiple indications in China, but this marks the first US approval for the novel monoclonal ...

Penpulimab-kcqx, a humanized immunoglobulin G1 monoclonal antibody, blocks the interaction between the programmed death 1 receptor on T-cells and programmed death ligand 1 and 2 on tumor cells.

In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 ...

Following a positive readout for its closely watched PD-1xVEGF bispecific ivonescimab, Akeso has won the FDA’s go-ahead for ...

A study demonstrates that radiologic imaging significantly alters management strategies in nearly half of high-risk cutaneous ...